Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

ons.

"The decision to trigger data cutoff and analysis based on trial duration relies on our level of confidence that the assumptions in the sample size calculations are appropriate; the most significant of which is the behavior of the control group. The guidance from the independent DMB combined with simulations we have performed based on the long-term follow-up from our Phase 2 trial gives us confidence that the timing of this analysis will provide adequate patient follow-up needed to retain the pre-specified statistical power of the trial. It is important to note that the DMB assessment was performed in a manner which ensured blinding and the integrity of this pivotal Phase 3 trial."

Third Quarter 2007 Financial Review

Favrille also reported its financial results for the third quarter of 2007. For the three and nine months ended September 30, 2007, the Company reported net losses of $12.3 million, or $0.37 per share, and $35.2 million, or $1.10 per share, respectively, compared to a net loss of $9.6 million, or $0.33 per share, and $30.3 million, or $1.13 per share, for the same periods in 2006.

Research and development expense was approximately $9.5 million and $27.1 million for the three and nine months ended September 30, 2007, respectively, compared to approximately $7.5 million and $23.4 million for the same periods in 2006. The increases were primarily due to additional expenses for personnel and stock-based compensation and increases in validation, rent and operating costs, supplies and depreciation related to the commercial-scale manufacturing facility expansion; offset by decreases in expenses associated with the pivotal Phase 3 clinical trial, which completed patient enrollment in January 2006. Total stock-based compensation included in research and development was approximately $670,000 and $1.7 million for the three and nine months ended September 30, 2007, respectively, compared to approximately $458,000 and $1.4 million for t
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources Group finds ... Australia , China , ... Korea—will expand at a strong rate through 2023. Dental implant procedure ... and as patient awareness rises. Other key findings from ... dental implant market: , Dental implant penetration: ...
(Date:9/30/2014)... 2014 According to ... by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments ... Application (Immunology, Oncology) & by End User ... MarketsandMarkets, provides a detailed overview of the ... trends, and strategies impacting the global glycomics ...
(Date:9/30/2014)... ANGELES , Sept. 30, 2014   Easy ... shopping destination , today announced that it now offers ... . AirSense CPAPs are the first sleep apnea therapy ... it simple and easy to track and share real-time ... overall effectiveness of their CPAP therapy.  In addition, the ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... National Heart, Lung and Blood Institute has awarded a ... Beverly Torok-Storb, Ph.D., both members of the Clinical Research ... Center grants represent part of a $170 million effort ... stem- and progenitor-cell tools and therapies. , The seven-year ...
... N.J., Oct. 7 BD (Becton, Dickinson and Company) (NYSE: ... announced that it is pleased to have been ranked in ... the 500 largest U.S. corporations based on environmental performance, policies ... 83rd overall. , Additionally, BD has been selected as ...
Cached Medicine Technology:Two Hutchinson Center Scientists Receive a Total of $16.7 Million for Collaborative Stem Cell Research 2BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes 2
(Date:10/1/2014)... October 01, 2014 NoteSwift Inc., announced ... versions 10.0, 12.1 and 13.0. NoteSwift is the bridge ... commands to navigate and document clinical information at the ... spends creating a patient note by more than half ... the major pain points providers state impedes EHR use ...
(Date:10/1/2014)... October 01, 2014 Scientists at the ... drugs that target immune system proteins has the power ... just posted details of the new study on their ... , Researchers in the UWA School of Pathology ... drugs to mice with mesothelioma with promising results. ...
(Date:10/1/2014)... Bahir Dar, Ethiopia, at the occasion of the ... some 150 African and international leishmaniasis experts, results ... and efficacy monitoring plan, carried out by ... Uganda, and Ethiopia, were presented to key decision ... treatment of kala-azar with the combination of Sodium ...
(Date:10/1/2014)... October is national Breast Cancer Awareness Month—an ... while raising money for breast cancer research. Pelican Water ... in the effort to find a cure. ... of having access to clean, healthy water. Research has ... certain forms of cancer. , The Problem of ...
(Date:10/1/2014)... Dr. Saj Jivraj, one of the world’s ... to Chennai, India, tomorrow to speak at the Indian ... , Dr. Jivraj is founder of the Anacapa Dental ... one of the world’s foremost prosthodontists, meaning he is ... speaking to the Indian Society of Oral Implantologists about ...
Breaking Medicine News(10 mins):Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... , FRIDAY, Jan. 28 (HealthDay News) -- Vailia Dennis says she ... anyone else,s timetable. Dennis, 91, of Rancho Bernardo, Calif., signed ... with a fatal heart condition. At the time, she was told ... condition that I have, is one that should have and could ...
... States is facing an unprecedented crisis in our health care ... College of Physicians (ACP), at today,s annual State of the ... health insurance coverage. We have more uninsured people than ... access to primary care. Health care costs are increasing at ...
... together? In this case, they become like a power couple, where ... API2 and MALT1 are two proteins that become fused together ... connects with an enzyme called NIK. When it does, MALT1 comes ... cleavage. The result? NIK is stronger than ever. It sheds ...
... sleep apnea who undergo surgery to improve their breathing get ... the day, according to a new study from Henry Ford ... greatly reduces daytime sleepiness a common side effect from ... completely blocked during sleep when compared to other non-surgical ...
... Only 42 percent of Americans say they sleep well almost ... according to a new National Sleep Foundation survey. The ... of about one hour more shuteye than others. On weekdays, ... nine minutes of slumber per night, compared with an average ...
... URBANA A new University of Illinois study provides ... your broccoli matters, and also suggests that teaming broccoli ... almost twice as powerful. "Broccoli, prepared correctly, is ... week are enough to have an effect. To get ...
Cached Medicine News:Health News:Woman's Life Refutes a Hospice Myth 2Health News:ACP says Congress must find 'common ground' to address 'crisis in our health care system' 2Health News:ACP says Congress must find 'common ground' to address 'crisis in our health care system' 3Health News:Study reveals how fusion protein triggers cancer 2Health News:Surgery for obstructive sleep apnea reduces daytime drowsiness 2Health News:Loving Your Bedroom May Be Key to Good Sleep 2Health News:Sprouts? Supplements? Team them up to boost broccoli's cancer-fighting power 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: